Add to ORKGA new generation of prostate cancer (PCa) biomarkers has emerged, including diagnostic serum and urine markers aimed at refining the identification high-grade tumors and tissue-based gene expression assays offering prognostic and predictive clinical information. Such tests seek to improve treatment-related decisions at multiple decision points, including initial diagnosis and following initial primary therapy. In this review, we aim to contextualize the body of evidence surrounding these emerging tests, with attention on studies addressing clinical utility
The widespread use of the PSA test has led to increased detection of the disease at earlier stages a...
International audienceActive surveillance (AS) in prostate cancer (PCa) represents a curative altern...
International audienceActive surveillance (AS) in prostate cancer (PCa) represents a curative altern...
A new generation of prostate cancer (PCa) biomarkers has emerged, including diagnostic serum and uri...
The diagnostics and management of localized prostate cancer is complicated because of cancer heterog...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
Worldwide, prostate cancer (PC) is the second-most-frequently diagnosed male cancer and the fifth-mo...
Active surveillance (AS) is now an accepted management strategy for men with low-risk localized pros...
The review initially provides a short introduction to prostate cancer (PCa) incidence, mortality, an...
International audienceActive surveillance (AS) in prostate cancer (PCa) represents a curative altern...
The widespread use of the PSA test has led to increased detection of the disease at earlier stages a...
Context: Prostate cancer (PCa) is the second most common type of cancer in men. Individualized risk ...
Context: Prostate cancer (PCa) is the second most common type of cancer in men. Individualized risk ...
The widespread use of the PSA test has led to increased detection of the disease at earlier stages a...
International audienceActive surveillance (AS) in prostate cancer (PCa) represents a curative altern...
International audienceActive surveillance (AS) in prostate cancer (PCa) represents a curative altern...
A new generation of prostate cancer (PCa) biomarkers has emerged, including diagnostic serum and uri...
The diagnostics and management of localized prostate cancer is complicated because of cancer heterog...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
Worldwide, prostate cancer (PC) is the second-most-frequently diagnosed male cancer and the fifth-mo...
Active surveillance (AS) is now an accepted management strategy for men with low-risk localized pros...
The review initially provides a short introduction to prostate cancer (PCa) incidence, mortality, an...
International audienceActive surveillance (AS) in prostate cancer (PCa) represents a curative altern...
The widespread use of the PSA test has led to increased detection of the disease at earlier stages a...
Context: Prostate cancer (PCa) is the second most common type of cancer in men. Individualized risk ...
Context: Prostate cancer (PCa) is the second most common type of cancer in men. Individualized risk ...
The widespread use of the PSA test has led to increased detection of the disease at earlier stages a...
International audienceActive surveillance (AS) in prostate cancer (PCa) represents a curative altern...
International audienceActive surveillance (AS) in prostate cancer (PCa) represents a curative altern...